LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Aandelen Lijst・Kura Oncology Inc

Kura Oncology Inc

Gesloten

SectorGezondheidszorg

10.2 2.41

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.13

Max

10.25

Belangrijke statistieken
By Trading Economics
Inkomsten	7.7M -73M
Verkoop	929K 18M
EPS	-0.828
Winstmarge	-401.495
Werknemers	260
EBITDA	7.4M -78M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+181.95% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	159M 1B
Vorige openingsprijs	7.79
Vorige sluitingsprijs	10.2

Nieuwssentiment

By Acuity

50%

161 / 344 Rangschikking in Healthcare

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 mei 2026, 23:08 UTC

Acquisities, Fusies, Overnames

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 mei 2026, 23:06 UTC

Acquisities, Fusies, Overnames

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 mei 2026, 20:53 UTC

Winsten

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 mei 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

29 mei 2026, 20:33 UTC

Marktinformatie

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 mei 2026, 20:11 UTC

Winsten

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mei 2026, 19:47 UTC

Winsten

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 mei 2026, 19:36 UTC

Marktinformatie

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 mei 2026, 19:34 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

29 mei 2026, 19:34 UTC

Marktinformatie

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 mei 2026, 19:22 UTC

Marktinformatie

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 mei 2026, 19:05 UTC

Acquisities, Fusies, Overnames

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 mei 2026, 18:19 UTC

Marktinformatie

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 mei 2026, 18:12 UTC

Acquisities, Fusies, Overnames

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 mei 2026, 18:11 UTC

Marktinformatie

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 mei 2026, 18:10 UTC

Marktinformatie

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 mei 2026, 17:55 UTC

Winsten

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mei 2026, 17:55 UTC

Marktinformatie

NEAR Protocol Nearly Doubles in May -- Market Talk

29 mei 2026, 17:38 UTC

Marktinformatie

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 mei 2026, 17:00 UTC

Winsten

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 mei 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

29 mei 2026, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

29 mei 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

29 mei 2026, 16:02 UTC

Marktinformatie

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 mei 2026, 15:55 UTC

Marktinformatie

Global Equities Roundup: Market Talk

29 mei 2026, 15:55 UTC

Marktinformatie

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29 mei 2026, 15:50 UTC

Acquisities, Fusies, Overnames

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29 mei 2026, 15:50 UTC

Acquisities, Fusies, Overnames

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29 mei 2026, 15:40 UTC

Marktinformatie

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29 mei 2026, 15:20 UTC

Marktinformatie

Canada's Economy Not Looking All That Bright -- Market Talk

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

181.95% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.11 USD 181.95%

Hoogste 40 USD

Laagste 15 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Kura Oncology Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

161 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.